Safety investigation of Fexuprazan, a gastric acid secretion inhibitor, in patients with cirrhosis
- Conditions
- Diseases of the digestive system
- Registration Number
- KCT0009189
- Lead Sponsor
- Soonchunhyang University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 99
Test group: ? Liver cirrhosis patients between 20 and 75 years old
?Milan gastroesophageal reflux requiring endoscopic drug treatment within the last 6 months
Patients with liver cirrhosis who have been diagnosed with the disease
Control group: ? Patients with no evidence of disease between the ages of 20 and 75
?Patients with no evidence of liver disease in blood tests or imaging tests
? Milan gastroesophageal reflux disease was diagnosed by endoscopy within the last 6 months.
Patients who took P-CAB
1. Patients with non-targeted liver cirrhosis who have variceal hemorrhage, hepatic encephalopathy, Gansin syndrome, or spontaneous peritonitis
2. Patients who have experienced side effects after previously using Proton Pump Inhibitor
3.Patients with untreated malignant tumor
4. Pregnant patients
5. Patients who did not consent to participate in the study
6. If you have taken fexuprazan at least 6 months prior to the time of Inclusion
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in liver values (AST or ALT) due to taking P-CAB
- Secondary Outcome Measures
Name Time Method Occurrence of spontaneous bacterial peritonitis